Prot #BB2121-MM-003: A Phase 3, Multicenter, Randomized, Open-Label Study to Compare The Efficacy and Safety of BB2121 Versus Standard Triplet Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)

Project: Research project

Project Details

StatusActive
Effective start/end date7/17/19 → 7/17/25

Funding

  • Celgene Corporation ((OE) Prot #BB2121-MM-003:)